News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

NICE Thumbs-up for Roche (RHHBY)'s MabThera as Maintenance Therapy


5/24/2011 7:04:02 AM

The UK's cost watchdog has recommended expanded use of Roche's lymphoma drug MabThera.

The National Institute for Health and Clinical Excellence has issued new draft guidance which recommends MabThera (rituximab) as a first-line maintenance treatment in people with follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab in combination with chemotherapy.

NICE notes that standard clinical practice for these patients, around 1,600 in the UK, is for doctors to wait for the cancer to grow again following successful induction therapy, before giving them further treatment. However evidence presented by Roche and advice from clinical specialists suggest that treating patients with MabThera maintenance after induction therapy "can prevent the spread and growth of this cancer by three to four years".



comments powered by Disqus
Roche
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES